Research programme: CRTh2 antagonists - Pulmagen Therapeutics
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pulmagen Therapeutics
- Class Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-asthma in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (PO)
- 14 Jul 2010 Preclinical trials in Acute asthma in United Kingdom (PO)